- Home
- News
- Topics
- FDA Week
- Inside CMS
- Inside Drug Pricing
- Health Exchange Alert
- Inside TeleHealth
- About Us
As Senate Finance Committee lawmakers continue talks on a measure to boost biosimilars using formulary levers, the pharmacy benefit manager industry strongly opposes the idea and is lobbying Congress to instead allow brand biologics to be automatically switched to biosimilars, including those deemed non-interchangeable by FDA.
Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.
Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.
© 2002-2025. Inside Washington Publishers | Contact Us